Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
CTSO

CTSO - CytoSorbents Corp Stock Price, Fair Value and News

1.08USD0.00 (0.00%)Market Closed

Market Summary

CTSO
USD1.080.00
Market Closed
0.00%

CTSO Stock Price

View Fullscreen

CTSO RSI Chart

CTSO Valuation

Market Cap

58.7M

Price/Earnings (Trailing)

-2.13

Price/Sales (Trailing)

1.6

EV/EBITDA

-1.98

Price/Free Cashflow

-2.5

CTSO Price/Sales (Trailing)

CTSO Profitability

EBT Margin

-77.29%

Return on Equity

-145.5%

Return on Assets

-58.51%

Free Cashflow Yield

-39.98%

CTSO Fundamentals

CTSO Revenue

Revenue (TTM)

36.7M

Rev. Growth (Yr)

3.56%

Rev. Growth (Qtr)

12.9%

CTSO Earnings

Earnings (TTM)

-27.5M

Earnings Growth (Yr)

13.21%

Earnings Growth (Qtr)

-8.96%

Breaking Down CTSO Revenue

Last 7 days

16.5%

Last 30 days

23.3%

Last 90 days

21.8%

Trailing 12 Months

-72.2%

How does CTSO drawdown profile look like?

CTSO Financial Health

Current Ratio

1.49

Debt/Equity

0.1

Debt/Cashflow

-12.12

CTSO Investor Care

Shares Dilution (1Y)

23.55%

Diluted EPS (TTM)

-0.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202436.7M000
202335.4M36.4M37.1M36.3M
202241.3M37.7M36.1M34.7M
202142.9M45.1M44.3M43.2M
202028.5M32.0M36.5M41.0M
201922.8M23.2M23.6M24.9M
201817.0M19.2M21.1M22.5M
201710.8M12.2M13.6M15.2M
20165.9M7.1M8.2M9.5M
20153.8M3.7M3.9M4.8M
20143.1M3.8M4.1M4.1M
20131.7M1.9M2.2M2.4M
2012366.9K697.8K1.0M1.4M
2011216.9K126.5K036.1K
2010000307.3K

Tracking the Latest Insider Buys and Sells of CytoSorbents Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 02, 2024
deliargyris efthymios
acquired
-
-
61,000
chief medical officer
Apr 02, 2024
chan phillip p.
acquired
-
-
96,000
chief executive officer
Apr 02, 2024
bloch kathleen p.
acquired
-
-
65,000
chief financial officer
Apr 02, 2024
capponi vincent
acquired
-
-
81,000
president and coo
Dec 13, 2023
chan phillip p.
bought
100,000
1.33
75,188
chief executive officer
Dec 13, 2023
bloch kathleen p.
bought
50,000
1.33
37,594
chief financial officer
Dec 13, 2023
jones edward raymond
bought
10,000
1.33
7,519
-
Dec 13, 2023
capponi vincent
bought
25,000
1.33
18,797
president & coo
Dec 13, 2023
sobel alan d.
bought
30,000
1.33
22,557
-
Dec 13, 2023
bator michael g.
bought
50,000
1.33
37,594
-

1–10 of 50

Which funds bought or sold CTSO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 12, 2024
Hexagon Capital Partners LLC
unchanged
-
-822
2,344
-%
Jul 09, 2024
LAZARD ASSET MANAGEMENT LLC
added
16.2
-
1,000
-%
May 20, 2024
Virtu Financial LLC
sold off
-100
-22,000
-
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
44,322
44,322
-%
May 16, 2024
COMERICA BANK
added
61.27
219
795
-%
May 16, 2024
AVENIR CORP
added
3.98
-372,995
3,014,060
0.26%
May 15, 2024
STATE STREET CORP
reduced
-7.15
-34,435
133,278
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
30.37
791
7,623
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
reduced
-44.75
-39,073
35,053
-%
May 15, 2024
Regal Investment Advisors LLC
reduced
-74.88
-39,931
10,934
-%

1–10 of 46

Are Funds Buying or Selling CTSO?

Are funds buying CTSO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CTSO
No. of Funds

Unveiling CytoSorbents Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
granahan investment management, llc
6.93%
3,618,143
SC 13G
Feb 14, 2024
avenir corp
6.87%
3,051,402
SC 13G
Jan 08, 2024
skylands capital, llc
7.3%
3,254,213
SC 13G
Feb 14, 2023
avenir corp
5.61%
2,447,089
SC 13G/A
Feb 09, 2023
vanguard group inc
4.48%
1,956,828
SC 13G/A
Feb 07, 2023
skylands capital, llc
5.8%
2,542,091
SC 13G
Jul 08, 2022
blackrock inc.
1.7%
744,958
SC 13G
Jun 28, 2022
avenir corp
4.95%
2,156,833
SC 13G/A
Apr 25, 2022
avenir corp
5.00%
2,177,146
SC 13G
Feb 09, 2022
vanguard group inc
5.08%
2,209,165
SC 13G/A

Recent SEC filings of CytoSorbents Corp

View All Filings
Date Filed Form Type Document
Jul 05, 2024
8-K
Current Report
Jun 10, 2024
8-K
Current Report
May 22, 2024
8-K
Current Report
May 09, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
May 06, 2024
8-K
Current Report
Apr 19, 2024
DEFA14A
DEFA14A
Apr 19, 2024
DEF 14A
DEF 14A
Apr 19, 2024
ARS
ARS

Peers (Alternatives to CytoSorbents Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.4B
40.3B
-0.11% -3.23%
32.23
4.5
-2.84% -3.00%
66.3B
19.7B
-2.03% -11.81%
49.7
3.36
4.82% -17.56%
18.3B
3.9B
-8.91% -34.05%
39.51
4.66
5.72% 46.72%
18.0B
14.9B
6.06% -24.38%
6.8
1.21
2.98% 207.68%
MID-CAP
9.6B
3.5B
-0.84% 23.59%
30.63
2.7
6.16% 35.06%
8.7B
2.6B
7.36% -23.54%
-26.9
3.33
-6.25% -68.58%
8.3B
12.4B
-1.91% -20.63%
21.5
0.67
-0.93% -18.83%
5.3B
3.9B
-5.66% -38.40%
-55.51
1.35
0.23% 90.80%
3.5B
387.1M
1.19% 34.50%
-217.1
8.93
30.82% 65.57%
2.1B
6.6B
6.39% -25.90%
11.49
0.33
1.50% -10.09%
SMALL-CAP
1.4B
3.2B
-7.99% -17.25%
-2.03
0.44
7.94% -1695.32%
402.3M
169.3M
4.21% 7.17%
-5.24
2.38
7.49% -244.90%
240.3M
324.0M
-2.44% -38.18%
-1.25
0.74
-3.19% -337.41%
47.8M
50.5M
-12.26% -77.59%
-2.1
0.95
14.25% -10.06%
6.0M
3.5M
-17.31% -90.00%
-0.49
1.69
-0.62% -1.48%

CytoSorbents Corp News

Latest updates
MarketBeat13 Jul 202407:19 am
Defense World13 Jul 202405:41 am
Benzinga02 Jul 202407:00 am

CytoSorbents Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue12.9%9,786,2928,668,2158,810,8479,420,8219,449,4969,390,4748,111,3538,495,5588,691,42410,782,1959,760,41612,024,06910,598,84711,955,77610,546,6129,794,9038,707,3107,430,3116,095,0076,232,5265,191,629
Gross Profit23.7%6,570,5795,311,2805,606,8666,018,5505,455,3275,757,0363,617,3774,944,8566,413,7887,659,4527,297,4709,313,8527,847,4039,428,3587,656,2306,545,1366,322,4685,335,6214,398,7334,398,1603,453,040
Operating Expenses-21.7%11,496,09714,686,10412,957,06412,577,78713,346,92312,113,39212,634,71513,301,90614,204,92317,221,27412,703,47014,238,58510,699,59412,062,6239,615,8799,842,8038,801,22210,766,94910,026,2798,028,1577,738,233
  S&GA Expenses-7.6%8,567,2009,275,0478,104,3927,723,9528,463,2757,952,8928,735,0488,439,3679,160,82310,442,7107,776,5759,821,4907,709,7038,273,5307,282,3576,590,9036,316,9346,633,1946,107,8774,506,5164,758,084
  R&D Expenses-45.1%2,248,1914,096,4993,749,1973,668,8044,214,4153,401,9313,290,1494,183,4624,243,3656,137,3584,262,2063,699,3142,282,0522,685,7811,753,4552,406,0391,965,2863,558,4563,185,1052,929,6032,418,633
EBITDA Margin5.4%-0.72-0.76-0.62-0.72-0.88-0.95-1.14-0.94-0.71-0.56-0.36-0.23---------
Interest Expenses97.3%199,418101,093102,241102,22271,112--------243,790298,029266,949318,879327,004274,204230,652227,681
Income Taxes-------1,092,585----736,003----1,127,074----1,092,446---
Earnings Before Taxes4.4%-6,357,861-6,648,646-9,193,520-6,153,084-7,325,883-1,858,711-12,200,837-10,879,222-8,966,398-10,043,015-6,406,285-4,677,530-4,167,821-1,804,798-839,729-2,866,956-3,452,779-5,041,797-6,885,061-3,547,405-4,883,827
EBT Margin4.2%-0.77-0.81-0.66-0.76-0.91-0.98-1.17-0.96-0.73-0.59-0.38-0.25---------
Net Income-9.0%-6,357,861-5,834,907-9,193,520-6,153,084-7,325,883-766,128-12,200,837-10,879,222-8,966,398-9,307,012-6,406,285-4,677,530-4,167,821-677,724-839,729-2,866,956-3,452,779-3,949,351-6,885,061-3,547,405-4,883,827
Net Income Margin4.3%-0.75-0.78-0.63-0.73-0.88-0.95-1.15-0.94-0.71-0.57-0.36-0.23---------
Free Cashflow25.0%-4,874,950-6,502,908-5,348,625-6,723,838-3,617,880-5,553,764-7,374,557-12,563,917-8,829,409-7,024,026-5,025,085-2,824,861---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-11.6%47.0053.0048.0052.0057.0063.0062.0071.0083.0090.0095.0098.0087.0090.0010449.0044.0027.0029.0028.0031.00
  Current Assets-22.2%20.0026.0019.0024.0028.0034.0032.0042.0056.0064.0073.0077.0080.0082.0097.0042.0038.0021.0022.0022.0025.00
    Cash Equivalents-39.1%9.0014.008.0013.0021.0024.0024.0032.0045.0054.0061.0066.0068.0071.0088.0035.0026.0012.0016.0016.0020.00
  Inventory1.6%4.004.003.002.002.003.004.005.005.005.005.004.003.003.002.002.002.002.002.001.001.00
  Net PPE-3.1%10.0010.0010.0011.0011.0011.0011.0010.008.005.004.003.002.002.002.002.002.002.002.002.002.00
Liabilities-6.1%28.0030.0029.0028.0029.0028.0023.0024.0028.0027.0024.0024.0010.0011.0024.0025.0023.0024.0022.0017.0016.00
  Current Liabilities-7.7%13.0015.0012.0010.0010.0010.0010.0011.0015.0014.0011.0011.0010.0010.0017.0016.0011.0010.009.007.007.00
  Long Term Debt-24.2%2.003.004.005.00-5.00--------6.008.0011.0013.0012.009.008.00
    LT Debt, Current0%3.003.001.00-----------9.007.004.002.003.001.002.00
    LT Debt, Non Current-24.2%2.003.004.005.00-5.00--------6.008.0011.0013.0012.009.008.00
Shareholder's Equity-18.7%19.0023.0019.0024.0029.0035.0039.0048.0055.0063.0071.0074.0077.0079.0080.0024.0021.003.007.0012.0015.00
  Retained Earnings-2.3%-288-282-276-267-261-254-253-241-230-221-211-205-200-196-195-195-192-188-184-177-174
  Additional Paid-In Capital0.3%306305292290289287286285284283282281279278277219212192190189189
Shares Outstanding0.1%54.0054.0044.0044.0044.0044.0044.0044.0043.0043.0043.0043.00---------
Float----144-61.00-----263---306---179-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations24.6%-4,829-6,407-5,206-6,933-3,108-5,340-6,734-8,039-8,119-5,491-4,133-2,036-2,344-1,057-3,2841,938-3,209-4,124-5,208-3,188-4,237
  Share Based Compensation-12.9%7348431,0865708308691,0057617877979991,5586676501,0881,046729491802145228
Cashflow From Investing6.6%-127-135-257140-682-206-716-4,685-847-1,672-1,017-984-606-266-404-497-508-403-315-327-474
Cashflow From Financing-104.7%-57112,2106489316845,000---40.36-80.9259013077.00-15,14756,3817,23317,8827735,2201802,005
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CTSO Income Statement

2024-03-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 9,786,292$ 9,449,496
Cost of revenue3,215,7133,994,169
Gross profit6,570,5795,455,327
Operating expenses:  
Research and development2,248,1914,214,415
Legal, financial and other consulting680,706669,233
Selling, general and administrative8,567,2008,463,275
Total operating expenses11,496,09713,346,923
Loss from operations(4,925,518)(7,891,596)
Other income (expense):  
Interest income (expense), net(6,653)(63,170)
Miscellaneous income/(expense) (31,798)
Gain (Loss) on foreign currency transactions(1,425,690)660,681
Total other income (expense), net(1,432,343)565,713
Loss before benefit from income taxes(6,357,861)(7,325,883)
Net loss attributable to common stockholders$ (6,357,861)$ (7,325,883)
Basic net loss per common share$ (0.12)$ (0.17)
Diluted net loss per common share$ (0.12)$ (0.17)
Weighted average number of shares of common stock outstanding, basic54,262,79043,676,435
Weighted average number of shares of common stock outstanding, diluted54,262,79043,676,435
Comprehensive loss:  
Net loss$ (6,357,861)$ (7,325,883)
Other comprehensive income/(loss):  
Foreign currency translation adjustment1,223,175(608,208)
Comprehensive loss(5,134,686)(7,934,091)
Total product sales  
Revenue:  
Total revenue8,989,5207,910,039
CytoSorb sales  
Revenue:  
Total revenue8,964,7907,906,269
Other product sales  
Revenue:  
Total revenue24,7303,770
Grant income  
Revenue:  
Total revenue$ 796,772$ 1,539,457

CTSO Balance Sheet

2024-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current Assets:  
Cash and cash equivalents$ 8,608,380$ 14,131,137
Grants and accounts receivable, net of allowances of $48,229 and $49,663 as of March 31, 2024 and December 31, 2023, respectively6,765,2906,057,072
Inventories3,738,7673,680,129
Prepaid expenses and other current assets880,3631,834,485
Total current assets19,992,80025,702,823
Property and equipment, net9,748,65110,056,354
Restricted cash1,483,9581,483,958
Right-of-use assets11,925,29912,058,896
Other assets3,919,8973,958,603
Total Assets47,070,60553,260,634
Current Liabilities:  
Accounts payable2,399,4213,802,170
Lease liability - current portion392,617373,636
Current maturities of long-term debt2,500,0002,500,000
Accrued expenses and other current liabilities8,132,0637,870,149
Total current liabilities13,424,10114,545,955
Lease liability, net of current portion12,790,00812,896,659
Long-term debt net of current maturities1,928,5712,542,857
Total Liabilities28,142,68029,985,471
Commitments and Contingencies (Note 6)
Stockholders' Equity:  
Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common Stock, Par Value $0.001, 100,000,000 shares authorized; 54,293,555 and 54,240,265 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively54,29454,240
Additional paid-in capital305,984,268305,196,874
Accumulated other comprehensive income1,752,496529,321
Accumulated deficit(288,863,133)(282,505,272)
Total Stockholders' Equity18,927,92523,275,163
Total Liabilities and Stockholders' Equity$ 47,070,605$ 53,260,634
CTSO
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
 CEO
 WEBSITEcytosorbents.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES198

CytoSorbents Corp Frequently Asked Questions


What is the ticker symbol for CytoSorbents Corp? What does CTSO stand for in stocks?

CTSO is the stock ticker symbol of CytoSorbents Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CytoSorbents Corp (CTSO)?

As of Fri Jul 12 2024, market cap of CytoSorbents Corp is 58.65 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTSO stock?

You can check CTSO's fair value in chart for subscribers.

What is the fair value of CTSO stock?

You can check CTSO's fair value in chart for subscribers. The fair value of CytoSorbents Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CytoSorbents Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CTSO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CytoSorbents Corp a good stock to buy?

The fair value guage provides a quick view whether CTSO is over valued or under valued. Whether CytoSorbents Corp is cheap or expensive depends on the assumptions which impact CytoSorbents Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTSO.

What is CytoSorbents Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 12 2024, CTSO's PE ratio (Price to Earnings) is -2.13 and Price to Sales (PS) ratio is 1.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTSO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CytoSorbents Corp's stock?

In the past 10 years, CytoSorbents Corp has provided -0.171 (multiply by 100 for percentage) rate of return.